Bridgeway Capital Management LLC Lowers Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI)

Bridgeway Capital Management LLC cut its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 4.3% in the 4th quarter, HoldingsChannel reports. The fund owned 177,481 shares of the company’s stock after selling 8,000 shares during the period. Bridgeway Capital Management LLC’s holdings in Trevi Therapeutics were worth $731,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Barclays PLC increased its stake in Trevi Therapeutics by 180.8% in the third quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after purchasing an additional 61,317 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in Trevi Therapeutics by 220.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 100,517 shares of the company’s stock valued at $336,000 after buying an additional 69,167 shares during the period. SG Americas Securities LLC increased its stake in shares of Trevi Therapeutics by 14.5% during the 4th quarter. SG Americas Securities LLC now owns 26,792 shares of the company’s stock valued at $110,000 after acquiring an additional 3,387 shares during the last quarter. China Universal Asset Management Co. Ltd. purchased a new position in shares of Trevi Therapeutics during the 4th quarter worth about $67,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Trevi Therapeutics by 2.1% in the fourth quarter. Bank of New York Mellon Corp now owns 140,219 shares of the company’s stock worth $578,000 after acquiring an additional 2,935 shares during the last quarter. Hedge funds and other institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

Shares of Trevi Therapeutics stock opened at $6.60 on Monday. Trevi Therapeutics, Inc. has a twelve month low of $2.30 and a twelve month high of $7.39. The stock has a market cap of $659.29 million, a price-to-earnings ratio of -15.00 and a beta of 0.62. The company has a fifty day moving average price of $6.15 and a 200 day moving average price of $4.54.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.04. Analysts forecast that Trevi Therapeutics, Inc. will post -0.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $9.00 to $29.00 in a report on Monday, March 10th. D. Boral Capital reissued a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Needham & Company LLC reaffirmed a “buy” rating and issued a $24.00 target price on shares of Trevi Therapeutics in a research report on Tuesday, April 8th. HC Wainwright reiterated a “buy” rating and issued a $12.50 target price on shares of Trevi Therapeutics in a report on Wednesday, March 19th. Finally, B. Riley restated a “buy” rating and set a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Trevi Therapeutics has an average rating of “Buy” and a consensus price target of $17.56.

Insider Activity at Trevi Therapeutics

In other news, CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction on Friday, March 21st. The shares were sold at an average price of $6.58, for a total value of $34,630.54. Following the completion of the transaction, the chief executive officer now directly owns 213,313 shares in the company, valued at approximately $1,403,599.54. This represents a 2.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now directly owns 76,900 shares of the company’s stock, valued at approximately $519,075. The trade was a 51.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 24.37% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.